TO THE EDITOR: Chemotherapy for light chain (AL) amyloidosis is based on combinations developed for multiple myeloma.[1][1] A better understanding of susceptibility of the AL underlying clone to specific types of treatments[2][2] and the ability to identify cytogenetic patterns with different
No takes yet. Share an insight, caveat, or question.
Milani et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: